Trials / Completed
CompletedNCT02157792
M6620 First in Human Study
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- EMD Serono Research & Development Institute, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | M6620 | |
| DRUG | Gemcitabine | |
| DRUG | Cisplatin | |
| DRUG | Etoposide | |
| DRUG | Carboplatin | |
| DRUG | Irinotecan |
Timeline
- Start date
- 2012-12-10
- Primary completion
- 2020-03-11
- Completion
- 2020-03-11
- First posted
- 2014-06-06
- Last updated
- 2020-04-01
Locations
31 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT02157792. Inclusion in this directory is not an endorsement.